Please login to the form below

Not currently logged in
Email:
Password:

Bind Therapeutics

This page shows the latest Bind Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer set to snap up Bind’s assets for $20m

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant. Nano-engineering firm Bind Therapeutics has reached a $20m agreement with Pfizer for the purchase of the majority of its assets. ... Pfizer signed a $210m-plus nanomedicines deal with Bind in

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Fostering partnerships. Recent developments include agreements to license the WEE1 inhibitor MK-1775 from Merck &Co and a collaboration with Bind Therapeutics which puts a molecule discovered by AZ – an Aurora

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    Award. Smallpox vaccine research. 228. Bind Therapeutics/ Pfizer. Collaboration. Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins. ... 200. Bind Therapeutics/ AstraZeneca. Collaboration. Employ the Medicinal

  • Pharma deals during April 2013 Pharma deals during April 2013

    Being bound to Bind– a popular choice. Bind Therapeutics did particularly well as a result of the frenzy, signing global deals with Pfizer and AstraZeneca (AZ), both based on Bind's ... carrying nanotech drug BIND-014, designed to selectively target

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BIND Therapeutics appoints Andrew Hirsch as permanent CEO BIND Therapeutics appoints Andrew Hirsch as permanent CEO

    Nanomedicine company BIND Therapeutics has appointed Andrew Hirsch as president and chief executive, confirming him in the roles he has held on an interim basis since March. ... Before joining BIND Hirsch spent almost 10 years at Biogen, rising to VP of

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics